Pembrolizumab vs Tildrakizumab
Pembrolizumab vs Tildrakizumab: Overview
This comparison examines the pharmacological differences between Pembrolizumab and Tildrakizumab.
Mechanism of Action
Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.
Pharmacokinetics
Half-life: Pembrolizumab β 26 days.
Chemical Properties
Type: Pembrolizumab β Antibody; Tildrakizumab β Antibody.